Torrey Pines Investment

Viriom Inc is advancing breakthrough medicines that are effective and affordable with the ultimate goal of curing HIV, chronic HBV and respiratory infections in both developing and developed countries

• Avelas Biosciences Avelas is a clinical-stage drug-device company focused on developing and commercializing pegloprastide with the goal of revolutionizing cancer surgery with real-time margin detection

• Learn More Avelas is a clinical-stage drug-device company focused on developing and commercializing pegloprastide with the goal of revolutionizing cancer surgery with real-time margin detection

• Chromis Therapeutics Chromis Therapeutics focuses on the development of curative treatments for chronic HBV (Hepatitis B virus) infection, based on its advanced proprietary drug design and discovery platform

• Learn More Chromis Therapeutics focuses on the development of curative treatments for chronic HBV (Hepatitis B virus) infection, based on its advanced proprietary drug design and discovery platform

• i2020 Accelerator i2020 helps accelerate early stage drug discovery platforms towards advanced lead and clinical candidate level within a two-year time framework

• Learn More i2020 helps accelerate early stage drug discovery platforms towards advanced lead and clinical candidate level within a two-year time framework

• Leap Therapeutics Leap is focused on developing targeted and immuno-oncology therapeutics

• Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 protein

• Learn More Leap is focused on developing targeted and immuno-oncology therapeutics Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 protein

• Afraxis Afraxis' patented ESP (Enhanced Spine Profiling) technology produces rapid, high-information read-outs of synaptic networks from in-vivo/in-vitro/ex-vivo preparations

• Learn More Afraxis' patented ESP (Enhanced Spine Profiling) technology produces rapid, high-information read-outs of synaptic networks from in-vivo/in-vitro/ex-vivo preparations

• Vaxxas Vaxxas focuses on enhancing the performance of vaccines with its HD-MAP technology platform, which rapidly delivers vaccine to the abundant immune cells immediately below the skin surface

• Learn More Vaxxas focuses on enhancing the performance of vaccines with its HD-MAP technology platform, which rapidly delivers vaccine to the abundant immune cells immediately below the skin surface

• Context Therapeutics Context Therapeutics Inc

• , is a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers

• Learn More Context Therapeutics Inc , is a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers

“We help our portfolio companies with both product and corporate development by leveraging our expertise in drug discovery, including non-clinical and clinical studies, manufacturing and quality, as well as regulatory affairs.”

• Rouslan Michtchenko HEAD of i2020 ACCELERATOR HEAD of i2020 ACCELERATOR
• Michael G
• Palfreyman Head of Due Diligence Head of Due Diligence
• Simon Bennett BD&L ADVISOR i2020 ACCELERATOR BD&L ADVISOR i2020 ACCELERATOR
• Christopher Rex R&D PROGRAM MANAGER i2020 ACCELERATOR R&D PROGRAM MANAGER i2020 ACCELERATOR